What is the current size and annual growth rate of the dry age related macular degeneration (amd) market?
The dry age related macular degeneration (AMD) market size has grown strongly in recent years. It will grow from $4.49 billion in 2024 to $4.90 billion in 2025 at a compound annual growth rate (CAGR) of 9.1%. The growth in the historic period can be attributed to a rising aging population, increased prevalence of chronic diseases, rising awareness of eye health, a growing number of clinical trials focusing on dry AMD, and growing demand for minimally invasive treatments.
The dry age related macular degeneration (AMD) market size is expected to see strong growth in the next few years. It will grow to $6.86 billion in 2029 at a compound annual growth rate (CAGR) of 8.8%. The growth in the forecast period can be attributed to emerging novel therapies, increasing healthcare expenditure, rising utilization of laser photocoagulation therapy, advancements in genetic research, and a growing focus on personalized medicine. Major trends in the forecast period include advancements in diagnostic technologies, rising adoption of teleophthalmology, technologically advanced treatments, product approvals, and new product launches.
Get Your Free Sample of The Global Dry Age Related Macular Degeneration (AMD) Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21176&type=smp
Which major factors have contributed to the expansion of the dry age related macular degeneration (amd) market?
The growing geriatric population is expected to propel the growth of the dry age related macular degeneration (AMD) market going forward. The geriatric population refers to older adults, typically defined as individuals aged 65 years and older. The increasing geriatric population is due to several reasons, such as advancements in medical technology, better management of chronic diseases, increased life expectancy, and improved geriatric care. Dry age-related macular degeneration (AMD) helps the geriatric population by providing targeted treatments and management options that aim to slow disease progression, preserve vision, and improve the quality of life for older individuals affected by this condition. For instance, in June 2024, according to reports published by the National Council on Aging, a US-based organization, in 2022, there were approximately 57.8 million adults aged 65 and older, representing 17.3% of the total U.S. population. This marked an increase from 16.9% in 2021. Therefore, the growing geriatric population will drive the growth of the dry age-related macular degeneration (AMD) market.
How is the dry age related macular degeneration (amd) market segmented?
The dry age related macular degeneration (AMD) market covered in this report is segmented –
1) By Stages: Early Age-Related Macular Degeneration, Intermediate Age-Related Macular Degeneration, Late Age-Related Macular Degeneration
2) By Age Group: Above 75 Years, Above 60 Years, Above 40 Years
3) By Route Of Administration: Oral, Injectables
4) By End Users: Hospitals And Clinics, Diagnostic Centers, Academic And Research Institutes
Subsegments:
1) By Early Age-Related Macular Degeneration: Drusen Accumulation, Retinal Pigment Epithelium Changes
2) By Intermediate Age-Related Macular Degeneration: Larger Drusen Deposits, Increased Pigmentary Abnormalities
3) By Late Age-Related Macular Degeneration: Geographic Atrophy, Central Vision Loss
Order your report now for swift delivery
Who are the top competitors in the dry age related macular degeneration (amd) market?
Major companies operating in the dry age related macular degeneration (AMD) market are F Hoffmann-La Roche Ltd., Novartis AG, Bayer AG, Amgen Inc., Biogen Inc., Astellas Pharma Inc., Bausch Health Companies Inc., Lupin Ltd., Santen Pharmaceuticals Inc., Biocon Ltd., Alimera Sciences Inc., Apellis Pharmaceuticals Inc., Belite Bio Inc., Axol Bioscience Ltd., Alkeus Pharmaceuticals Inc., Kubota Holdings Co., Ribomic Inc., Eyestem Research Pvt. Ltd., LumiThera Inc., Adverum Biotechnologies Inc.
Which key trends are expected to influence the dry age related macular degeneration (amd) market in the coming years?
Major companies operating in the dry age related macular degeneration (AMD) market are focused on developing new advanced technologies and treatments, such as light delivery systems, to target and activate retinal cells, potentially slowing disease progression. Light delivery systems refer to technologies designed to transmit light for therapeutic applications, particularly in medical treatments. For instance, in January 2024, LumiThera Inc., a US-based medical device company, launched photobiomodulation (PBM) for dry age-related macular degeneration (AMD) with the Valeda Light Delivery System. This is the first FDA-authorized therapy designed to address vision loss in patients suffering from dry AMD, a condition that currently has limited treatment options. LumiThera initiated the EUROLIGHT registry study to gather long-term data on the outcomes of patients treated with the Valeda system. The Valeda system utilizes a multi-wavelength light delivery method that employs three specific wavelengths (590 nm, 660 nm, and 850 nm). This non-invasive treatment can be administered through either an open or closed eyelid and typically requires nine sessions over three to four weeks.
Which regional trends are influencing the dry age related macular degeneration (amd) market, and which area dominates the industry?
North America was the largest region in the dry age-related macular degeneration (AMD) market in 2024. The regions covered in the dry age related macular degeneration (AMD) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Dry Age Related Macular Degeneration (AMD) Market Report 2025 Offer?
The dry age related macular degeneration (amd) market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Dry age related macular degeneration (AMD) refers to a progressive eye condition characterized by the gradual deterioration of the macula, the central part of the retina, leading to blurred central vision. They are used for managing and slowing the progression of the disease through treatments like vitamins, nutritional supplements, and emerging pharmaceutical therapies.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21176
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
